;PMID: 2766464
;source_file_1020.mrg
;Release 0.9 of PennBioIE
;Funded by NSF ITR EIA-0205448

;0)section:[e:0..39] = [t:0..39]
;1)sentence:[e:45..262] = [t:45..262]
;2)section:[e:266..351] = [t:266..351]
;3)section:[e:355..475] = [t:355..475]
;4)sentence:[e:479..707] = [t:479..707]
;5)sentence:[e:708..1156] = [t:708..1156]
;6)sentence:[e:1157..1332] = [t:1157..1332]
;7)sentence:[e:1333..1481] = [t:1333..1481]
;8)sentence:[e:1482..1633] = [t:1482..1633]
;9)sentence:[e:1634..1792] = [t:1634..1792]
;10)sentence:[e:1793..2008] = [t:1793..2008]
;11)sentence:[e:2009..2108] = [t:2009..2108]
;12)section:[e:2112..2156] = [t:2112..2155]
;Sentence Matching Errors
;ERROR_Section end mismatch[e:2112..2156][t:2112..2155]
;Token/POS Errors
;ERROR_Token in entity file but not tree[2155..2156] ]

;section 0 Span:0..39
;Carcinogenesis. 1989 Sep;10(9):1719-24.
(SEC
  (FRAG (NNP:[0..14] Carcinogenesis) (,:[14..15] .) (CD:[16..20] 1989)
        (::[21..28] Sep;10-LRB-) (CD:[28..29] 9) (-RRB-:[29..30] -RRB-)
        (CD:[30..35] :1719) (::[35..36] -) (CD:[36..38] 24) (.:[38..39] .)))

;sentence 1 Span:45..262
;Lack of promoting effect of clonazepam on the development of 
;N-nitrosodiethylamine-initiated hepatocellular tumors in mice is correlated
;with  its inability to inhibit cell-to-cell communication in mouse
;hepatocytes.
;[73..83]:substance:"clonazepam"
;[107..128]:substance:"N-nitrosodiethylamine"
(SENT
  (S-HLN
    (NP-SBJ-1
      (NP (NN:[45..49] Lack))
      (PP (IN:[50..52] of)
        (NP
          (NP (VBG:[53..62] promoting) (NN:[63..69] effect))
          (PP (IN:[70..72] of)
            (NP (NN:[73..83] clonazepam)))
          (PP (IN:[84..86] on)
            (NP
              (NP (DT:[87..90] the) (NN:[91..102] development))
              (PP (IN:[103..105] of)
                (NP
                  (ADJP (NN:[107..128] N-nitrosodiethylamine)
                        (HYPH:[128..129] -) (VBN:[129..138] initiated))
                  (JJ:[139..153] hepatocellular) (NNS:[154..160] tumors)))
              (PP-LOC (IN:[161..163] in)
                (NP (NNS:[164..168] mice))))))))
    (VP (VBZ:[169..171] is)
      (VP (JJ:[172..182] correlated)
        (NP-1 (-NONE-:[182..182] *))
        (PP-CLR (IN:[183..187] with)
          (NP (PRP$:[189..192] its) (NN:[193..202] inability)
            (S
              (NP-SBJ (-NONE-:[202..202] *))
              (VP (TO:[203..205] to)
                (VP (VB:[206..213] inhibit)
                  (NP
                    (NML
                      (NML (NN:[214..218] cell))
                      (HYPH:[218..219] -)
                      (PP (TO:[219..221] to) (HYPH:[221..222] -)
                        (NP (NN:[222..226] cell))))
                    (NN:[227..240] communication))
                  (PP-LOC (IN:[241..243] in)
                    (NP (NN:[244..249] mouse) (NNS:[250..261] hepatocytes))))))))))
    (.:[261..262] .)))

;section 2 Span:266..351
;Diwan BA, Lubet RA, Nims RW, Klaunig JE, Weghorst CM, Henneman JR, Ward JM,
;Rice  JM.
(SEC
  (FRAG (NNP:[266..271] Diwan) (NNP:[272..274] BA) (,:[274..275] ,)
        (NNP:[276..281] Lubet) (NNP:[282..284] RA) (,:[284..285] ,)
        (NNP:[286..290] Nims) (NNP:[291..293] RW) (,:[293..294] ,)
        (NNP:[295..302] Klaunig) (NNP:[303..305] JE) (,:[305..306] ,)
        (NNP:[307..315] Weghorst) (NNP:[316..318] CM) (,:[318..319] ,)
        (NNP:[320..328] Henneman) (NNP:[329..331] JR) (,:[331..332] ,)
        (NNP:[333..337] Ward) (NNP:[338..340] JM) (,:[340..341] ,)
        (NNP:[342..346] Rice) (NNPS:[348..350] JM) (.:[350..351] .)))

;section 3 Span:355..475
;Biological Carcinogenesis and Development Program Resources, Inc., National 
;Cancer Institute, Frederick, MD 21701-1013.
(SEC
  (FRAG (NNP:[355..365] Biological) (NNP:[366..380] Carcinogenesis)
        (CC:[381..384] and) (NNP:[385..396] Development)
        (NNP:[397..404] Program) (NNPS:[405..414] Resources) (,:[414..415] ,)
        (NNP:[416..420] Inc.) (,:[420..421] ,) (NNP:[422..430] National)
        (NNP:[432..438] Cancer) (NNP:[439..448] Institute) (,:[448..449] ,)
        (NNP:[450..459] Frederick) (,:[459..460] ,) (NNP:[461..463] MD)
        (CD:[464..469] 21701) (::[469..470] -) (CD:[470..474] 1013)
        (.:[474..475] .)))

;sentence 4 Span:479..707
;The tumor-promoting ability of clonazepam (CZP), a widely used benzodiazepine
; anticonvulsant, was investigated in an in vivo mouse liver tumor promotion
;assay  and an in vitro mouse hepatocyte intercellular communication assay.
;[510..520]:substance:"clonazepam"
;[522..525]:substance:"CZP"
;[542..572]:substance:"benzodiazepine  anticonvulsant"
(SENT
  (S
    (NP-SBJ-1
      (NP (DT:[479..482] The)
        (ADJP (NN:[483..488] tumor) (HYPH:[488..489] -)
              (VBG:[489..498] promoting))
        (NN:[499..506] ability))
      (PP (IN:[507..509] of)
        (NP
          (NP
            (NP (NN:[510..520] clonazepam))
            (NP (-LRB-:[521..522] -LRB-) (NN:[522..525] CZP)
                (-RRB-:[525..526] -RRB-)))
          (,:[526..527] ,)
          (NP (DT:[528..529] a)
            (ADJP (RB:[530..536] widely) (VBN:[537..541] used))
             (NN:[542..556] benzodiazepine) (NN:[558..572] anticonvulsant)))))
    (,:[572..573] ,)
    (VP (VBD:[574..577] was)
      (VP (VBN:[578..590] investigated)
        (NP-1 (-NONE-:[590..590] *))
        (PP (IN:[591..593] in)
          (NP
            (NP (DT:[594..596] an)
              (ADJP (FW:[597..599] in) (FW:[600..604] vivo))
              (NML (NN:[605..610] mouse) (NN:[611..616] liver))
              (NML (NN:[617..622] tumor) (NN:[623..632] promotion))
              (NN:[633..638] assay))
            (CC:[640..643] and)
            (NP (DT:[644..646] an)
              (ADJP (FW:[647..649] in) (FW:[650..655] vitro))
              (NML (NN:[656..661] mouse) (NN:[662..672] hepatocyte))
              (NML (JJ:[673..686] intercellular) (NN:[687..700] communication))
              (NN:[701..706] assay))))))
    (.:[706..707] .)))

;sentence 5 Span:708..1156
;The  development of preneoplastic hepatocellular foci of cellular alteration
;and  hepatocellular neoplasms was studied in male B6C3F1 mice initiated, at 5
;weeks  of age, with a single i.p. injection of N-nitrosodiethylamine (NDEA;
;90 mg/kg  body weight) in tricaprylin, followed by administration of either
;phenobarbital  (PB; 0.05%) or CZP (0.068% or 0.136%) in diet beginning 2
;weeks after carcinogen  injection and continuing to 60 weeks of age.
;[861..862]:quantitative-value:"5"
;[863..868]:quantitative-units:"weeks"
;[910..931]:substance:"N-nitrosodiethylamine"
;[933..937]:substance:"NDEA"
;[939..941]:quantitative-value:"90"
;[942..960]:quantitative-units:"mg/kg  body weight"
;[965..976]:substance:"tricaprylin"
;[1015..1028]:substance:"phenobarbital"
;[1031..1033]:substance:"PB"
;[1035..1040]:quantitative-value:"0.05%"
;[1045..1048]:substance:"CZP"
;[1050..1056]:quantitative-value:"0.068%"
;[1060..1066]:quantitative-value:"0.136%"
;[1086..1087]:quantitative-value:"2"
;[1088..1093]:quantitative-units:"weeks"
;[1100..1110]:substance:"carcinogen"
;[1140..1142]:quantitative-value:"60"
;[1143..1148]:quantitative-units:"weeks"
(SENT
  (S
    (NP-SBJ-1
      (NP (DT:[708..711] The) (NN:[713..724] development))
      (PP (IN:[725..727] of)
        (NP
          (NP
            (NP (JJ:[728..741] preneoplastic) (JJ:[742..756] hepatocellular)
                (NNS:[757..761] foci))
            (PP (IN:[762..764] of)
              (NP (JJ:[765..773] cellular) (NN:[774..784] alteration))))
          (CC:[785..788] and)
          (NP (JJ:[790..804] hepatocellular) (NNS:[805..814] neoplasms)))))
    (VP (VBD:[815..818] was)
      (VP (VBN:[819..826] studied)
        (NP-1 (-NONE-:[826..826] *))
        (PP-LOC (IN:[827..829] in)
          (NP
            (NP (JJ:[830..834] male) (NN:[835..841] B6C3F1)
                (NNS:[842..846] mice))
            (VP (VBN:[847..856] initiated)
              (NP (-NONE-:[856..856] *))
              (,:[856..857] ,)
              (PP-TMP (IN:[858..860] at)
                (NP
                  (NP (CD:[861..862] 5) (NNS:[863..868] weeks))
                  (PP (IN:[870..872] of)
                    (NP (NN:[873..876] age)))))
              (,:[876..877] ,)
              (PP-MNR (IN:[878..882] with)
                (NP
                  (NP
                    (NP (DT:[883..884] a) (JJ:[885..891] single)
                        (NN:[892..896] i.p.) (NN:[897..906] injection))
                    (PP (IN:[907..909] of)
                      (NP
                        (NP
                          (NP (NN:[910..931] N-nitrosodiethylamine))
                          (NP (-LRB-:[932..933] -LRB-) (NN:[933..937] NDEA))
                          (PRN (::[937..938] ;)
                            (NP
                              (NP (CD:[939..941] 90) (NN:[942..944] mg))
                              (PP (SYM:[944..945] /)
                                (NP (NN:[945..947] kg) (NN:[949..953] body)
                                    (NN:[954..960] weight))))
                            (-RRB-:[960..961] -RRB-)))
                        (PP (IN:[962..964] in)
                          (NP (NN:[965..976] tricaprylin))))))
                  (,:[976..977] ,)
                  (VP (VBN:[978..986] followed)
                    (NP (-NONE-:[986..986] *))
                    (PP (IN:[987..989] by)
                      (NP-LGS
                        (NP
                          (NP (NN:[990..1004] administration))
                          (PP (IN:[1005..1007] of)
                            (NP (CC:[1008..1014] either)
                              (NP
                                (NP (NN:[1015..1028] phenobarbital))
                                (NP (-LRB-:[1030..1031] -LRB-)
                                    (NN:[1031..1033] PB))
                                (::[1033..1034] ;)
                                (PRN
                                  (NP (CD:[1035..1039] 0.05) (NN:[1039..1040] %))
                                  (-RRB-:[1040..1041] -RRB-)))
                              (CC:[1042..1044] or)
                              (NP (NN:[1045..1048] CZP)
                                (PRN (-LRB-:[1049..1050] -LRB-)
                                  (NP
                                    (NP (CD:[1050..1055] 0.068)
                                        (NN:[1055..1056] %))
                                    (CC:[1057..1059] or)
                                    (NP (CD:[1060..1065] 0.136)
                                        (NN:[1065..1066] %)))
                                  (-RRB-:[1066..1067] -RRB-)))))
                          (PP (IN:[1068..1070] in)
                            (NP (NN:[1071..1075] diet))))
                        (VP
                          (VP (VBG:[1076..1085] beginning)
                            (NP-TMP
                              (NP (CD:[1086..1087] 2) (NNS:[1088..1093] weeks))
                              (PP (IN:[1094..1099] after)
                                (NP (NN:[1100..1110] carcinogen)
                                    (NN:[1112..1121] injection)))))
                          (CC:[1122..1125] and)
                          (VP (VBG:[1126..1136] continuing)
                            (PP-TMP (TO:[1137..1139] to)
                              (NP
                                (NP (CD:[1140..1142] 60)
                                    (NNS:[1143..1148] weeks))
                                (PP (IN:[1149..1151] of)
                                  (NP (NN:[1152..1155] age)))))))))))))))))
    (.:[1155..1156] .)))

;sentence 6 Span:1157..1332
;Several mice from each group were  killed after 9, 21, 33 or 53 weeks on test
;diet, and portions of liver and other  organs were fixed in formalin and
;examined histologically.
;[1205..1206]:quantitative-value:"9"
;[1208..1210]:quantitative-value:"21"
;[1212..1214]:quantitative-value:"33"
;[1218..1220]:quantitative-value:"53"
;[1221..1226]:quantitative-units:"weeks"
;[1295..1303]:substance:"formalin"
(SENT
  (S
    (S
      (NP-SBJ-2
        (NP (JJ:[1157..1164] Several) (NNS:[1165..1169] mice))
        (PP (IN:[1170..1174] from)
          (NP (DT:[1175..1179] each) (NN:[1180..1185] group))))
      (VP (VBD:[1186..1190] were)
        (VP (VBN:[1192..1198] killed)
          (NP-2 (-NONE-:[1198..1198] *))
          (PP-TMP (IN:[1199..1204] after)
            (NP
              (NP
                (NP (CD:[1205..1206] 9)
                  (NML-1 (-NONE-:[1206..1206] *P*)))
                (,:[1206..1207] ,)
                (NP (CD:[1208..1210] 21)
                  (NML-1 (-NONE-:[1210..1210] *P*)))
                (,:[1210..1211] ,)
                (NP (CD:[1212..1214] 33)
                  (NML-1 (-NONE-:[1214..1214] *P*)))
                (CC:[1215..1217] or)
                (NP (CD:[1218..1220] 53)
                  (NML-1 (NNS:[1221..1226] weeks))))
              (PP (IN:[1227..1229] on)
                (NP (NN:[1230..1234] test) (NN:[1235..1239] diet))))))))
    (,:[1239..1240] ,) (CC:[1241..1244] and)
    (S
      (NP-SBJ-3
        (NP (NNS:[1245..1253] portions))
        (PP (IN:[1254..1256] of)
          (NP
            (NP (NN:[1257..1262] liver))
            (CC:[1263..1266] and)
            (NP (JJ:[1267..1272] other) (NNS:[1274..1280] organs)))))
      (VP (VBD:[1281..1285] were)
        (VP
          (VP (VBN:[1286..1291] fixed)
            (NP-3 (-NONE-:[1291..1291] *))
            (PP (IN:[1292..1294] in)
              (NP (NN:[1295..1303] formalin))))
          (CC:[1304..1307] and)
          (VP (VBN:[1308..1316] examined)
            (NP-3 (-NONE-:[1316..1316] *))
            (ADVP (RB:[1317..1331] histologically))))))
    (.:[1331..1332] .)))

;sentence 7 Span:1333..1481
;Unlike PB, CZP did  not promote the development of preneoplastic
;hepatocellular foci or neoplasms  (adenomas and carcinomas) in NDEA-initiated
;mice.
;[1340..1342]:substance:"PB"
;[1344..1347]:substance:"CZP"
;[1461..1465]:substance:"NDEA"
(SENT
  (S
    (PP (IN:[1333..1339] Unlike)
      (NP (NN:[1340..1342] PB)))
    (,:[1342..1343] ,)
    (NP-SBJ (NN:[1344..1347] CZP))
    (VP (VBD:[1348..1351] did) (RB:[1353..1356] not)
      (VP (VB:[1357..1364] promote)
        (NP
          (NP (DT:[1365..1368] the) (NN:[1369..1380] development))
          (PP (IN:[1381..1383] of)
            (NP
              (NP (JJ:[1384..1397] preneoplastic)
                  (JJ:[1398..1412] hepatocellular) (NNS:[1413..1417] foci))
              (CC:[1418..1420] or)
              (NP (NNS:[1421..1430] neoplasms)
                (PRN (-LRB-:[1432..1433] -LRB-)
                  (NP (NNS:[1433..1441] adenomas) (CC:[1442..1445] and)
                      (NNS:[1446..1456] carcinomas))
                  (-RRB-:[1456..1457] -RRB-))))))
        (PP-LOC (IN:[1458..1460] in)
          (NP
            (ADJP (NN:[1461..1465] NDEA) (HYPH:[1465..1466] -)
                  (VBN:[1466..1475] initiated))
            (NNS:[1476..1480] mice)))))
    (.:[1480..1481] .)))

;sentence 8 Span:1482..1633
;Following limited (2 weeks)  dietary exposure at 0.15%, CZP was a potent
;inducer of hepatic P450IIB1-mediated  alkoxyresorufin O-dealkylase
;activities.
;[1501..1502]:quantitative-value:"2"
;[1503..1508]:quantitative-units:"weeks"
;[1531..1536]:quantitative-value:"0.15%"
;[1538..1541]:substance:"CZP"
;[1555..1562]:substance:"inducer"
;[1574..1582]:cyp450:"P450IIB1"
;[1593..1621]:substance:"alkoxyresorufin O-dealkylase"
(SENT
  (S
    (PP (VBG:[1482..1491] Following)
      (NP
        (NP (VBN:[1492..1499] limited)
          (PRN (-LRB-:[1500..1501] -LRB-)
            (NP (CD:[1501..1502] 2) (NNS:[1503..1508] weeks))
            (-RRB-:[1508..1509] -RRB-))
          (JJ:[1511..1518] dietary) (NN:[1519..1527] exposure))
        (PP (IN:[1528..1530] at)
          (NP (CD:[1531..1535] 0.15) (NN:[1535..1536] %)))))
    (,:[1536..1537] ,)
    (NP-SBJ (NN:[1538..1541] CZP))
    (VP (VBD:[1542..1545] was)
      (NP-PRD
        (NP (DT:[1546..1547] a) (JJ:[1548..1554] potent)
            (NN:[1555..1562] inducer))
        (PP (IN:[1563..1565] of)
          (NP (JJ:[1566..1573] hepatic)
            (ADJP (NN:[1574..1582] P450IIB1) (HYPH:[1582..1583] -)
                  (VBN:[1583..1591] mediated))
            (NML (NN:[1593..1608] alkoxyresorufin)
                 (NN:[1609..1621] O-dealkylase))
            (NNS:[1622..1632] activities)))))
    (.:[1632..1633] .)))

;sentence 9 Span:1634..1792
;In contrast, the degree of induction in  hepatic tissue from mice fed 0.136%
;CZP for 53 weeks was markedly lower than  that in mice fed 0.05% PB for 53
;weeks.
;[1704..1710]:quantitative-value:"0.136%"
;[1711..1714]:substance:"CZP"
;[1719..1721]:quantitative-value:"53"
;[1722..1727]:quantitative-units:"weeks"
;[1770..1775]:quantitative-value:"0.05%"
;[1776..1778]:substance:"PB"
;[1783..1785]:quantitative-value:"53"
;[1786..1791]:quantitative-units:"weeks"
(SENT
  (S
    (PP (IN:[1634..1636] In)
      (NP (NN:[1637..1645] contrast)))
    (,:[1645..1646] ,)
    (NP-SBJ
      (NP (DT:[1647..1650] the) (NN:[1651..1657] degree))
      (PP (IN:[1658..1660] of)
        (NP (NN:[1661..1670] induction)))
      (PP-LOC (IN:[1671..1673] in)
        (NP
          (NP (JJ:[1675..1682] hepatic) (NN:[1683..1689] tissue))
          (PP (IN:[1690..1694] from)
            (NP
              (NP (NNS:[1695..1699] mice))
              (VP (VBN:[1700..1703] fed)
                (NP (-NONE-:[1703..1703] *))
                (NP
                  (NML (CD:[1704..1709] 0.136) (NN:[1709..1710] %))
                  (NN:[1711..1714] CZP))
                (PP-TMP (IN:[1715..1718] for)
                  (NP (CD:[1719..1721] 53) (NNS:[1722..1727] weeks)))))))))
    (VP (VBD:[1728..1731] was)
      (ADJP-PRD
        (ADJP (RB:[1732..1740] markedly) (JJR:[1741..1746] lower))
        (PP (IN:[1747..1751] than)
          (NP
            (NP (DT:[1753..1757] that))
            (PP-LOC (IN:[1758..1760] in)
              (NP
                (NP (NNS:[1761..1765] mice))
                (VP (VBD:[1766..1769] fed)
                  (NP (-NONE-:[1769..1769] *))
                  (NP
                    (NML (CD:[1770..1774] 0.05) (NN:[1774..1775] %))
                    (NN:[1776..1778] PB))
                  (PP-TMP (IN:[1779..1782] for)
                    (NP (CD:[1783..1785] 53) (NNS:[1786..1791] weeks))))))))))
    (.:[1791..1792] .)))

;sentence 10 Span:1793..2008
;In the in vitro assay, diazepam, a  strong tumor promoter in mouse liver,
;significantly inhibited mouse hepatocyte  gap junctional intercellular
;communication, while CZP had no significant effect  on this parameter.
;[1816..1824]:substance:"diazepam"
;[1842..1850]:substance:"promoter"
;[1959..1962]:substance:"CZP"
(SENT
  (S
    (PP (IN:[1793..1795] In)
      (NP (DT:[1796..1799] the)
        (ADJP (FW:[1800..1802] in) (FW:[1803..1808] vitro))
        (NN:[1809..1814] assay)))
    (,:[1814..1815] ,)
    (NP-SBJ
      (NP (NN:[1816..1824] diazepam))
      (,:[1824..1825] ,)
      (NP
        (NP (DT:[1826..1827] a) (JJ:[1829..1835] strong) (NN:[1836..1841] tumor)
            (NN:[1842..1850] promoter))
        (PP-LOC (IN:[1851..1853] in)
          (NP (NN:[1854..1859] mouse) (NN:[1860..1865] liver)))))
    (,:[1865..1866] ,)
    (ADVP (RB:[1867..1880] significantly))
    (VP (VBD:[1881..1890] inhibited)
      (NP
        (NML (NN:[1891..1896] mouse) (NN:[1897..1907] hepatocyte))
        (ADJP (NN:[1909..1912] gap) (JJ:[1913..1923] junctional))
        (JJ:[1924..1937] intercellular) (NN:[1938..1951] communication))
      (,:[1951..1952] ,)
      (SBAR-ADV (IN:[1953..1958] while)
        (S
          (NP-SBJ (NN:[1959..1962] CZP))
          (VP (VBD:[1963..1966] had)
            (NP
              (NP (DT:[1967..1969] no) (JJ:[1970..1981] significant)
                  (NN:[1982..1988] effect))
              (PP (IN:[1990..1992] on)
                (NP (DT:[1993..1997] this) (NN:[1998..2007] parameter))))))))
    (.:[2007..2008] .)))

;sentence 11 Span:2009..2108
;Thus, CZP, a drug structurally related to diazepam, is  inactive as a liver
;tumor promoter in mice.
;[2015..2018]:substance:"CZP"
;[2022..2026]:substance:"drug"
;[2051..2059]:substance:"diazepam"
;[2091..2099]:substance:"promoter"
(SENT
  (S
    (ADVP (RB:[2009..2013] Thus))
    (,:[2013..2014] ,)
    (NP-SBJ
      (NP (NN:[2015..2018] CZP))
      (,:[2018..2019] ,)
      (NP
        (NP (DT:[2020..2021] a) (NN:[2022..2026] drug))
        (VP
          (ADVP (RB:[2027..2039] structurally))
          (JJ:[2040..2047] related)
          (NP (-NONE-:[2047..2047] *))
          (PP-CLR (TO:[2048..2050] to)
            (NP (NN:[2051..2059] diazepam))))))
    (,:[2059..2060] ,)
    (VP (VBZ:[2061..2063] is)
      (ADJP-PRD (JJ:[2065..2073] inactive))
      (PP (IN:[2074..2076] as)
        (NP (DT:[2077..2078] a) (JJ:[2079..2084] liver) (NN:[2085..2090] tumor)
            (NN:[2091..2099] promoter)))
      (PP-LOC (IN:[2100..2102] in)
        (NP (NNS:[2103..2107] mice))))
    (.:[2107..2108] .)))

;section 12 Span:2112..2155
;PMID: 2766464 [PubMed - indexed for MEDLINE
(SEC
  (FRAG (NNP:[2112..2116] PMID) (::[2116..2117] :) (CD:[2118..2125] 2766464)
        (-LRB-:[2126..2127] -LSB-) (NNP:[2127..2133] PubMed) (::[2134..2135] -)
        (VBN:[2136..2143] indexed) (IN:[2144..2147] for)
        (NNP:[2148..2155] MEDLINE)))
;ERROR_Orphan Text from EOF Tree File[2155..EOF] ]

(ORPH -RSB-)
